CCI-779 in Treating Patients With Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 27, 2001

Primary Completion Date

May 4, 2006

Study Completion Date

December 15, 2007

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

temsirolimus

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Comprehensive Cancer Center, Madison

90095

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

94143

UCSF Comprehensive Cancer Center, San Francisco

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

48109-0942

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

78284-6220

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00022724 - CCI-779 in Treating Patients With Malignant Glioma | Biotech Hunter | Biotech Hunter